Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 6/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | SELE | P16581 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | PDXK | O00764 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2874874 | 0.86 | PDE4D (0.38) | PDE4DICAM1SELEVCAM1PDE4A | |
| SCHEMBL844835 | 0.78 | PDXK (0.36) | PDE4DICAM1SELEVCAM1PDXK | |
| SCHEMBL321133 | 0.74 | PDXK (0.40) | PDE4DICAM1SELEVCAM1PDXK | |
| SCHEMBL23374480 | 0.71 | GALR3 (0.46) | P2RX7 | |
| SCHEMBL29718773 | 0.71 | GALR3 (0.46) | P2RX7 | |
| SCHEMBL11273660 | 0.71 | ROCK2 (0.40) | CYP3A4 | |
| SCHEMBL7356678 | 0.71 | PDE4D (0.45) | PDE4DICAM1SELEVCAM1PDE4A | |
| SCHEMBL1565002 | 0.71 | ALDH1A1 (0.35) | PDE4DPDE4A | |
| SCHEMBL1563060 | 0.70 | PDE4D (0.36) | PDE4DPDXKPDE4AP2RX7BDKRB2 | |
| SCHEMBL1564959 | 0.70 | SLC6A2 (0.38) | PDE4DPDXKP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410134-B2 | 8-oxy-quinoline derivatives as bradykinin B2 receptor modulators | SHIRE ORPHAN THERAPIES GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2144897-B1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | JERINI AG (DE) | 2010-10-20 | — | — | EP | disclosed |
| US-20100234344-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | JERINI AG (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2144897-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | Jerini AG (DE) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008116620-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | JERINI AG (DE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234344-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | BDKRB2, BDKRB1, HRH2 | PDE4D 1366/4885ICAM1 2641/4885SELE 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.